title: T-cell lymphoproliferative disorder potentially induced by imatinib in a patient with GIST.
abstract: BACKGROUND
  A 71-year-old male patient was diagnosed as having a KIT-positive gastrointestinal stromal tumor located at the gastric antrum. With no signs of distant metastasis, the patient primarily underwent gastric surgery with antrectomy and Billroth-I-reconstruction. Owing to tumor size and mitotic index, the patient was considered at high risk of tumor relapse and thus was entered into a clinical trial to receive adjuvant imatinib treatment. 4 months after initiation of imatinib treatment, the patient presented with several newly discovered subcutaneous and intra-abdominal tumor lesions. Imatinib treatment had been tolerated well until then.
  
  
  METHODS
  Physical examination, blood tests, biopsies of the subcutaneous tumor lesions, tumor morphology and immunohistochemistry, PCR for the T-cell receptor gamma genes, sequential CT and PET-CT.
  
  
  METHODS
  Monoclonal T-cell lymphoproliferative disorder, potentially induced by imatinib.
  
  
  RESULTS
  Imatinib was stopped, after which the tumor lesions spontaneously regressed and, eventually, complete remission was achieved.
authors.affiliation: III Medical Department, Klinikum rechts der Isar, Technical University Munich, Ismaningerstrasse 22, 81675 München, Germany.
authors.forename: Mareike
authors.initials: M
authors.lastname: Verbeek
authors.forename: Falko
authors.initials: F
authors.lastname: Fend
authors.forename: Thomas
authors.initials: T
authors.lastname: Licht
authors.forename: Christian Meyer zum
authors.initials: CM
authors.lastname: Büschenfelde
authors.forename: Jens
authors.initials: J
authors.lastname: Stollfuss
authors.forename: Christian
authors.initials: C
authors.lastname: Peschel
authors.forename: Justus
authors.initials: J
authors.lastname: Duyster
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D017024:Chemotherapy, Adjuvant; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D013601:T-Lymphocytes / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate